JP2009508511A - ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 - Google Patents
ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 Download PDFInfo
- Publication number
- JP2009508511A JP2009508511A JP2008531733A JP2008531733A JP2009508511A JP 2009508511 A JP2009508511 A JP 2009508511A JP 2008531733 A JP2008531733 A JP 2008531733A JP 2008531733 A JP2008531733 A JP 2008531733A JP 2009508511 A JP2009508511 A JP 2009508511A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- cell
- human
- hcms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 210000000329 smooth muscle myocyte Anatomy 0.000 title claims abstract description 40
- 102000043827 human Smooth muscle Human genes 0.000 title claims abstract description 20
- 108700038605 human Smooth muscle Proteins 0.000 title claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 166
- 238000001964 muscle biopsy Methods 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 210000002363 skeletal muscle cell Anatomy 0.000 claims abstract description 32
- 238000000338 in vitro Methods 0.000 claims abstract description 31
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 102000006783 calponin Human genes 0.000 claims abstract description 17
- 108010086826 calponin Proteins 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 241000282412 Homo Species 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 64
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 38
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 20
- 230000004069 differentiation Effects 0.000 claims description 17
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 16
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 16
- 108010044052 Desmin Proteins 0.000 claims description 14
- 102100036912 Desmin Human genes 0.000 claims description 14
- 210000005045 desmin Anatomy 0.000 claims description 14
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 12
- 101710099061 Myogenic factor 5 Proteins 0.000 claims description 12
- 102100032970 Myogenin Human genes 0.000 claims description 12
- 108010056785 Myogenin Proteins 0.000 claims description 12
- 238000001574 biopsy Methods 0.000 claims description 12
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 11
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 5
- 229930182831 D-valine Natural products 0.000 claims description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 210000000107 myocyte Anatomy 0.000 claims description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 108010081589 Becaplermin Proteins 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 239000012091 fetal bovine serum Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 210000003098 myoblast Anatomy 0.000 claims description 4
- 230000001114 myogenic effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 208000037998 chronic venous disease Diseases 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 201000011531 vascular cancer Diseases 0.000 claims description 3
- 206010055031 vascular neoplasm Diseases 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- -1 FGFb Proteins 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 238000004115 adherent culture Methods 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- 210000005068 bladder tissue Anatomy 0.000 claims 1
- 238000005070 sampling Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 230000000250 revascularization Effects 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 24
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010042291 Serum Response Factor Proteins 0.000 description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004446 Serum Response Factor Human genes 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150084229 ATXN1 gene Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100022056 Serum response factor Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010055756 hemalin Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Excavating Of Shafts Or Tunnels (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0509557A FR2890977A1 (fr) | 2005-09-19 | 2005-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
| PCT/FR2006/002144 WO2007034069A1 (fr) | 2005-09-19 | 2006-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508511A true JP2009508511A (ja) | 2009-03-05 |
| JP2009508511A5 JP2009508511A5 (enExample) | 2012-10-04 |
Family
ID=36587333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008531733A Pending JP2009508511A (ja) | 2005-09-19 | 2006-09-19 | ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090269310A1 (enExample) |
| EP (1) | EP1934333B9 (enExample) |
| JP (1) | JP2009508511A (enExample) |
| CN (1) | CN101310013B (enExample) |
| AT (1) | ATE531791T1 (enExample) |
| AU (1) | AU2006293814B2 (enExample) |
| CA (1) | CA2622916A1 (enExample) |
| FR (1) | FR2890977A1 (enExample) |
| IL (1) | IL190289A0 (enExample) |
| WO (1) | WO2007034069A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526229A (ja) * | 2019-03-22 | 2022-05-24 | インノヴァセル アーゲー | 誘導平滑筋細胞を得るための方法 |
| WO2024143453A1 (ja) * | 2022-12-28 | 2024-07-04 | インターステム株式会社 | 細胞組成物 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2909559B1 (fr) * | 2006-12-06 | 2012-09-07 | Inst Vaisseaux Et Du Sang | Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation |
| KR101724639B1 (ko) * | 2008-11-04 | 2017-04-07 | 리젠메드 (케이만) 엘티디. | 세포-지지체 구조물 |
| HRP20230474T1 (hr) * | 2017-12-14 | 2023-07-21 | Innovacell Ag | Postupci za dobivanje stanica izvedenih iz mišića |
| CN112119155A (zh) * | 2018-05-08 | 2020-12-22 | 苏黎士大学 | 用于无异种产生hMPC群的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535586A (ja) * | 2000-06-07 | 2003-12-02 | アシスタンス ピュブリク−オピトー ドゥ パリ | 筋組織由来の特徴づけされた細胞集団の獲得プロセス及びその利用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247575A1 (en) * | 2003-06-03 | 2004-12-09 | Caplice Noel M. | Smooth muscle progenitor cells |
-
2005
- 2005-09-19 FR FR0509557A patent/FR2890977A1/fr not_active Withdrawn
-
2006
- 2006-09-19 EP EP06808166A patent/EP1934333B9/fr not_active Not-in-force
- 2006-09-19 CN CN2006800428874A patent/CN101310013B/zh not_active Expired - Fee Related
- 2006-09-19 US US12/067,218 patent/US20090269310A1/en not_active Abandoned
- 2006-09-19 JP JP2008531733A patent/JP2009508511A/ja active Pending
- 2006-09-19 AU AU2006293814A patent/AU2006293814B2/en not_active Ceased
- 2006-09-19 AT AT06808166T patent/ATE531791T1/de active
- 2006-09-19 WO PCT/FR2006/002144 patent/WO2007034069A1/fr not_active Ceased
- 2006-09-19 CA CA002622916A patent/CA2622916A1/fr not_active Abandoned
-
2008
- 2008-03-19 IL IL190289A patent/IL190289A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535586A (ja) * | 2000-06-07 | 2003-12-02 | アシスタンス ピュブリク−オピトー ドゥ パリ | 筋組織由来の特徴づけされた細胞集団の獲得プロセス及びその利用 |
Non-Patent Citations (5)
| Title |
|---|
| JPN6012014765; Ｃａｒｄｉｏｖａｓｃｕｌａｒ Ｒｅｓ． Ｖｏｌ．６２, 2004, ｐ．１７６-１８４ * |
| JPN6012014766; 実験医学 Ｖｏｌ．１８， Ｎｏ．５, 2000, ｐ．１３８-１４４ * |
| JPN6012014767; Ｃｏｎｎｅｃｔｉｖｅ Ｔｉｓｓｕｅ Ｖｏｌ．３４, 2002, ｐ．１７５-１７９ * |
| JPN6012014768; Ｄｅｖｅｌｏｐｍｅｎｔ Ｖｏｌ．１２７, 2000, ｐ．１６２７-１６３９ * |
| JPN6012014769; Ｄｅｖｅｌｏｐ．Ｂｉｏｌ． Ｖｏｌ．１７２, 1995, ｐ．４２２-４３９ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022526229A (ja) * | 2019-03-22 | 2022-05-24 | インノヴァセル アーゲー | 誘導平滑筋細胞を得るための方法 |
| JP7616665B2 (ja) | 2019-03-22 | 2025-01-17 | インノヴァセル ゲーエムベーハー | 誘導平滑筋細胞を得るための方法 |
| US12312600B2 (en) | 2019-03-22 | 2025-05-27 | Innovacell Gmbh | Methods for obtaining induced smooth muscle cells |
| WO2024143453A1 (ja) * | 2022-12-28 | 2024-07-04 | インターステム株式会社 | 細胞組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006293814B2 (en) | 2011-09-29 |
| FR2890977A1 (fr) | 2007-03-23 |
| CN101310013B (zh) | 2011-09-07 |
| US20090269310A1 (en) | 2009-10-29 |
| EP1934333A1 (fr) | 2008-06-25 |
| CA2622916A1 (fr) | 2007-03-29 |
| IL190289A0 (en) | 2011-08-01 |
| ATE531791T1 (de) | 2011-11-15 |
| CN101310013A (zh) | 2008-11-19 |
| EP1934333B1 (fr) | 2011-11-02 |
| AU2006293814A1 (en) | 2007-03-29 |
| EP1934333B9 (fr) | 2012-05-02 |
| WO2007034069A1 (fr) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell | |
| CN112891374B (zh) | 治疗中风的影响的方法 | |
| WO2007061750A2 (en) | Adipose tissue derived stromal cells for the treatment of neurological disorders | |
| CN106727703B (zh) | 治疗移植物抗宿主疾病的方法 | |
| JP2007143554A (ja) | 細胞移植方法及び試薬 | |
| CN111803523A (zh) | 利用间充质干细胞的肺动脉高血压的治疗 | |
| Bossolasco et al. | Skeletal muscle differentiation potential of human adult bone marrow cells | |
| JP2023133612A (ja) | 膵島移植のための改善された方法 | |
| JP2011519574A (ja) | 細胞ベースの治療に関連する材料および方法 | |
| Kögler et al. | Future of cord blood for non-oncology uses | |
| JP2011519574A5 (enExample) | ||
| CN111163787A (zh) | 用于靶向组织修复的血小板囊泡工程化的细胞和细胞外囊泡 | |
| TW201000110A (en) | Method of differentiating mammalian progenitor cells into insulin producing pancreatic islet cells | |
| WO2016161290A1 (en) | Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms | |
| Yang et al. | Nicotinamide facilitates mesenchymal stem cell differentiation into insulin-producing cells and homing to pancreas in diabetic mice | |
| JP2009508511A (ja) | ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 | |
| JP2009508511A5 (enExample) | ||
| AU2004286322A1 (en) | Novel multipotent stem cells and use thereof | |
| US11963983B2 (en) | Methods of cardiac repair | |
| US20090155220A1 (en) | Use of Bone-Marrow Derived Stem Cells to Treat Ischemia | |
| US20050232905A1 (en) | Use of peripheral blood cells for cardiac regeneration | |
| JP4083024B6 (ja) | 細胞移植方法及び試薬 | |
| WO2007138577A2 (en) | Methods of generating a neural tissue using muscle-derived cells | |
| HK1238561A1 (en) | Method of treating graft versus host disease | |
| Zeng | Swine bone marrow-derived multipotent adult stem cells and its application in swine hearts with postinfarction LV dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120621 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120718 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120725 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |